An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate057
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Aug 2018 This trial has been completed in Austria.
    • 05 Jun 2018 Results (n=1720) of preliminary data of pooled analysis (CA209057, the KEYNOTE-010 and the OAK trial) assessing the role of immunotherapy for second line treatment of advanced, pre-treated, non-squamous Non-small-cell-lung-cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2018 Results assessing the relationship between response status at a landmark and subsequent overall survival presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top